Top

Published in:

01-09-2019 | Melanoma | Clinical Trial Report

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

Authors: Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo Antonio Ascierto, Stefano Cascinu, Jürgen C. Becker, Axel Hauschild, Antonella Romanini, Riccardo Danielli, Reinhard Dummer, Uwe Trefzer, Giuliano Elia, Dario Neri, Claus Garbe

Published in: Cancer Immunology, Immunotherapy | Issue 9/2019

Abstract

Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune checkpoint inhibitors. Here we describe the results of a controlled, randomized phase II clinical trial, aimed at assessing the therapeutic potential of L19IL2, a fully human fusion protein consisting of the L19 antibody specific to the alternatively spliced extra-domain B of fibronectin, fused to human interleukin-2 in advanced metastatic melanoma. In one arm, patients received dacarbazine (DTIC; 1000 mg/m² of body surface on day 1 of 21-day cycles) as single agent, while in two other arms L19IL2 (22.5 million international units of IL2 equivalents) was added, based on two different schedules of administration. In total, 69 patients with stage IV melanoma were enrolled (24 in the dacarbazine arm, 23 and 22 in the other combination arms, respectively) and 67 received treatment. Analyses of efficacy results show a statistically significant benefit in terms of overall response rate and median progression-free survival for patients receiving L19IL2 in combination with DTIC, compared to DTIC as single agent. In light of these results, further clinical investigations with L19IL2 (alone or in combination with other agents) are warranted.

Available only for authorised users

Korn EL, Liu PY, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26(4):527–534. https://doi.org/10.1200/JCO.2007.12.7837 CrossRefPubMed

Garbe C, Peris K, Hauschild A et al (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46(2):270–283. https://doi.org/10.1016/j.ejca.2009.10.032 CrossRefPubMed

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948):1109–1117. https://doi.org/10.1016/S0140-6736(14)60958-2 CrossRefPubMed

Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526. https://doi.org/10.1056/NEJMoa1104621 CrossRefPubMed

Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X CrossRefPubMed

Falchook GS, Lewis KD, Infante JR et al (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782–789. https://doi.org/10.1016/S1470-2045(12)70269-3 CrossRefPubMedPubMedCentral

Falchook GS, Long GV, Kurzrock R et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901. https://doi.org/10.1016/S0140-6736(12)60398-5 CrossRefPubMedPubMedCentral

Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714. https://doi.org/10.1056/NEJMoa1112302 CrossRefPubMedPubMedCentral

10.

Smith FO, Downey SG, Klapper JA et al (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14(17):5610–5618. https://doi.org/10.1158/1078-0432.CCR-08-0116 CrossRefPubMedPubMedCentral

11.

Atkins MB (2009) Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 26(Suppl 1):18–22. https://doi.org/10.1007/s12032-008-9148-x CrossRefPubMed

12.

Herper M (2018) Bristol-Myers to pay largest fee in biotech history for Nektar cancer drug. Forbes. Retrieved from https://www.forbes.com/sites/matthewherper/2018/02/14/bristol-myers-to-paylargest-licensing-fee-in-biotech-history-for-cancer-drug/#5e90fc0a6d29

13.

Penichet ML, Dela Cruz JS, Shin SU, Morrison SL (2001) A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 10(1):43–49CrossRefPubMed

14.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL et al (2012) Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol 189(5):2656–2664. https://doi.org/10.4049/jimmunol.1200934 CrossRefPubMedPubMedCentral

15.

Neri D, Sondel PM (2016) Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40:96–102. https://doi.org/10.1016/j.coi.2016.03.006 CrossRefPubMedPubMedCentral

16.

Carnemolla B, Borsi L, Balza E et al (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5):1659–1665. https://doi.org/10.1182/blood.V99.5.1659 CrossRefPubMed

17.

Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113(10):2275–2283. https://doi.org/10.1182/blood-2008-05-160747 CrossRefPubMed

18.

Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133(3):751–758. https://doi.org/10.1038/jid.2012.376 CrossRefPubMed

19.

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA (2009) Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med 7:68. https://doi.org/10.1186/1479-5876-7-68 CrossRefPubMedPubMedCentral

20.

Shusterman S, London WB, Gillies SD et al (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol 28(33):4969–4975. https://doi.org/10.1200/jco.2009.27.8861 CrossRefPubMedPubMedCentral

21.

Lansigan F, Nakamura R, Quick D, Vlock D, Raubitschek AA, Gillies SD, Bachanova V (2016) Phase I/II study of an anti-CD20-interleukin-2 immunocytokine DI-Leu16-IL2 in patients with relapsed b-cell lymphoma (NHL). J Clin Oncol 34(15_suppl):e19046. https://doi.org/10.1200/jco.2016.34.15_suppl.e19046 CrossRef

22.

Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5(201):201ra118. https://doi.org/10.1126/scitranslmed.3006221 CrossRefPubMed

23.

Catania C, Maur M, Berardi R et al (2015) The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhes Migr 9(1–2):14–21. https://doi.org/10.4161/19336918.2014.983785 CrossRef

24.

Weide B, Eigentler TK, Pflugfelder A et al (2014) Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res 2(7):668–678. https://doi.org/10.1158/2326-6066.CIR-13-0206 CrossRefPubMed

25.

Johannsen M, Spitaleri G, Curigliano G et al (2010) The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46(16):2926–2935. https://doi.org/10.1016/j.ejca.2010.07.033 CrossRefPubMed

26.

Eigentler TK, Weide B, de Braud F et al (2011) A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 17(24):7732–7742. https://doi.org/10.1158/1078-0432.CCR-11-1203 CrossRefPubMed

27.

Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L (2010) Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 127(1):101–110. https://doi.org/10.1002/ijc.25018 CrossRefPubMed

28.

Balza E, Mortara L, Sassi F et al (2006) Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 12(8):2575–2582. https://doi.org/10.1158/1078-0432.CCR-05-2448 CrossRefPubMed

29.

Gutbrodt KL, Casi G, Neri D (2014) Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 13(7):1772–1776. https://doi.org/10.1158/1535-7163.MCT-14-0105 CrossRefPubMed

30.

Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14(20):6515–6524. https://doi.org/10.1158/1078-0432.CCR-07-5041 CrossRefPubMed

31.

Mortara L, Balza E, Sassi F et al (2007) Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Eur J Immunol 37(12):3381–3392. https://doi.org/10.1002/eji.200737450 CrossRefPubMed

32.

Rekers NH, Zegers CM, Yaromina A et al (2015) Combination of radiotherapy with the immunocytokine L19-IL2: additive effect in a NK cell dependent tumour model. Radiother Oncol 116(3):438–442. https://doi.org/10.1016/j.radonc.2015.06.019 CrossRefPubMed

33.

Zegers CM, Rekers NH, Quaden DH et al (2015) Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 21(5):1151–1160. https://doi.org/10.1158/1078-0432.CCR-14-2676 CrossRefPubMed

34.

Spitaleri G, Berardi R, Pierantoni C et al (2013) Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol 139(3):447–455. https://doi.org/10.1007/s00432-012-1327-7 CrossRefPubMed

35.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

36.

Frey K, Fiechter M, Schwager K, Belloni B, Barysch MJ, Neri D, Dummer R (2011) Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol 20(8):685–688. https://doi.org/10.1111/j.1600-0625.2011.01314.x CrossRefPubMed

37.

Schwartzentruber DJ (2001) Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24(4):287–293CrossRefPubMed

38.

Ma C, Armstrong AW (2014) Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat 25(5):401–408. https://doi.org/10.3109/09546634.2013.813897 CrossRefPubMed

39.

Wu CF, Wang HM, Huang WK, Chang JW (2015) Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. Asia Pac J Clin Oncol 11(4):314–318. https://doi.org/10.1111/ajco.12404 CrossRefPubMed

40.

Erba PA, Sollini M, Orciuolo E et al (2012) Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J. Nuclear Med. 53(6):922–927. https://doi.org/10.2967/jnumed.111.101006 CrossRef

41.

Poli GL, Bianchi C, Virotta G et al (2013) Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res 1(2):134–143. https://doi.org/10.1158/2326-6066 CrossRefPubMed

42.

Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20(3):264–269. https://doi.org/10.1038/nbt0302-264 CrossRefPubMed

43.

Rodig SJ, Gusenleitner D, Jackson DG et al (2018) MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aar3342 CrossRefPubMed

44.

Schliemann C, Gutbrodt KL, Kerkhoff A et al (2015) Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Res 3(5):547–556. https://doi.org/10.1158/2326-6066.CIR-14-0179 CrossRefPubMed

45.

Murphy K, Weaver C (2017) Janeway's immunobiology, 9th edn. Garland Science, Taylor & Francis Group, LLC, New York, p 823

46.

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093 CrossRefPubMed

47.

Patel SP, Milton D, Milhem MM et al (2016) Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma. J Clin Oncol 34(15_suppl):e21041–e21041. https://doi.org/10.1200/jco.2016.34.15_suppl.e21041 CrossRef

48.

Klein C, Waldhauer I, Nicolini VG et al (2017) Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6(3):e1277306. https://doi.org/10.1080/2162402X.2016.1277306 CrossRefPubMedPubMedCentral

49.

Hutmacher C, Gonzalo Nunez N, Liuzzi AR, Becher B, Neri D (2019) Targeted DELIVERY of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8(+) T cells. Cancer Immunol Res 7(4):572–583. https://doi.org/10.1158/2326-6066.CIR-18-0566 CrossRefPubMedPubMedCentral

50.

De Luca R, Neri D (2018) Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. Cancer Immunol Immunother 67(9):1381–1391. https://doi.org/10.1007/s00262-018-2194-0 CrossRefPubMedPubMedCentral

51.

Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59(5):612–618CrossRefPubMed

52.

Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33(12):1718–1722. https://doi.org/10.1016/j.leukres.2009.06.025 CrossRefPubMed

53.

Sauer S, Erba PA, Petrini M et al (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113(10):2265–2274. https://doi.org/10.1182/blood-2008-06-160416 CrossRefPubMed

54.

Kaspar M, Zardi L, Neri D (2006) Fibronectin as target for tumor therapy. Int J Cancer 118(6):1331–1339. https://doi.org/10.1002/ijc.21677 CrossRefPubMed

Title: A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Authors: Benjamin Weide
Thomas Eigentler
Chiara Catania
Paolo Antonio Ascierto
Stefano Cascinu
Jürgen C. Becker
Axel Hauschild
Antonella Romanini
Riccardo Danielli
Reinhard Dummer
Uwe Trefzer
Giuliano Elia
Dario Neri
Claus Garbe
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Melanoma
Melanoma
Published in: Cancer Immunology, Immunotherapy / Issue 9/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02383-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2019

Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone

Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer

Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials

Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer